{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:38:06Z","timestamp":1793122686634,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.diabres.2026.113520","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:34:00Z","timestamp":1787614440000},"page":"113520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of incident diabetes after initiation of 5\u03b1-reductase inhibitor plus \u03b1-blocker combination therapy: A nationwide cohort study with age-specific analyses"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9778-2613","authenticated-orcid":false,"given":"Eonji","family":"Na","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-6714","authenticated-orcid":false,"given":"Bora","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonggi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113520_b0005","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia: epidemiology, risk factors, and pathophysiology","volume":"301","author":"Chan","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113520_b0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3803\/EnM.2015.30.3.263","article-title":"Diabetes in Asians","volume":"30","author":"Rhee","year":"2015","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113520_b0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4111\/icu.20230249","article-title":"The epidemiology of male lower urinary tract symptoms associated with benign prostatic hyperplasia: results of 20 years of Korean community care and surveys","volume":"65","author":"Jeh","year":"2024","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.diabres.2026.113520_b0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","article-title":"The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"5","author":"Kim","year":"2018","journal-title":"Asian J Urol"},{"key":"10.1016\/j.diabres.2026.113520_b0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023","volume":"211","author":"Sandhu","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.diabres.2026.113520_b0030","unstructured":"European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. https:\/\/uroweb.org\/guidelines\/archive\/management-of-non-neurogenic-male-luts; 2023 [accessed 20 January 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0035","doi-asserted-by":"crossref","first-page":"E1397","DOI":"10.1210\/jc.2014-1395","article-title":"5\u03b1-Reductase type 1 modulates insulin sensitivity in men","volume":"99","author":"Upreti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113520_b0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2015-2928","article-title":"Dual-5\u03b1-reductase inhibition promotes hepatic lipid accumulation in man","volume":"101","author":"Hazlehurst","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113520_b0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.21037\/tau-22-690","article-title":"5-alpha reductase inhibitors use in prostatic disease and beyond","volume":"12","author":"Chislett","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.diabres.2026.113520_b0050","author":"Wei"},{"key":"10.1016\/j.diabres.2026.113520_b0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5489\/cuaj.7489","article-title":"The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: a population-based study","volume":"15","author":"Johnstone","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.diabres.2026.113520_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.23097","article-title":"5-alpha-reductase inhibitors and the risk of diabetes mellitus: a nationwide population-based study","volume":"76","author":"Lee","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.diabres.2026.113520_b0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3349\/ymj.2025.0056","article-title":"Risk of type 2 diabetes mellitus in new users of 5-alpha reductase inhibitors: a nationwide historical cohort study","volume":"67","author":"Nguyen","year":"2026","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.diabres.2026.113520_b0070","unstructured":"European Medicines Agency. PRAC recommendations on signals adopted at the 13\u201316 May 2019 PRAC meeting. https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf; 2019 [accessed 25 January 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0075","unstructured":"European Medicines Agency. PRAC recommendations on signals adopted at the 28\u201331 October 2019 PRAC meeting. https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-28-31-october-2019-prac-meeting_en.pdf; 2019 [accessed 25 January 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0080","unstructured":"Saudi Food and Drug Authority. Safety signal of finasteride and the risk of diabetes mellitus. https:\/\/www.sfda.gov.sa\/sites\/default\/files\/2021-08\/FINASTERIDE-DIABETES_MELLITUS.pdf; 2021 [accessed 25 January 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0085","unstructured":"Saudi Food and Drug Authority. Safety signal of dutasteride and the risk of diabetes mellitus. https:\/\/www.sfda.gov.sa\/sites\/default\/files\/2022-05\/DutasterideRiskDiabetesMellitus_0.pdf; 2022 [accessed 25 January 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0090","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabres.2026.113520_b0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.diabres.2026.113520_b0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113520_b0105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-159-8-201310150-00709","article-title":"Randomized trials analyzed as observational studies","volume":"159","author":"Hern\u00e1n","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2026.113520_b0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time\u2010varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113520_b0115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/pds.5620","article-title":"Tell me what you want, what you really really want: estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies","volume":"32","author":"Luijken","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113520_b0120","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.diabres.2026.113520_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016640","article-title":"Cohort profile: the national health insurance service-national health screening cohort (NHIS-HEALS) in Korea","volume":"7","author":"Seong","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2026.113520_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4093\/dmj.2024.0780","article-title":"Big data research for diabetes-related diseases using the Korean national health information database","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113520_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4093\/dmj.2022.0375","article-title":"Comparison of operational definition of type 2 diabetes mellitus based on data from Korean national health insurance service and Korea national health and nutrition examination survey","volume":"47","author":"Baek","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113520_b0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113520_b0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113520_b0150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","article-title":"Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis","volume":"68","author":"Movahedi","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.diabres.2026.113520_b0155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2337\/dc19-1175","article-title":"Association between the use of antidepressants and the risk of type 2 diabetes: a large, population-based cohort study in Japan","volume":"43","author":"Miidera","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113520_b0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13098-019-0509-8","article-title":"Age-specific diabetes risk by the number of metabolic syndrome components: a Korean nationwide cohort study","volume":"11","author":"Lee","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2026.113520_b0165","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41598-020-59203-z","article-title":"Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2026.113520_b0170","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.diabres.2026.113520_b0175","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.diabres.2026.113520_b0180","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat - Simul Comput"},{"key":"10.1016\/j.diabres.2026.113520_b0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.diabres.2026.113520_b0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-020-01037-0","article-title":"Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study","volume":"19","author":"Na","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113520_b0195","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP guide on methodological standards in pharmacoepidemiology, Revision 11. https:\/\/encepp.europa.eu\/encepp-toolkit\/methodological-guide_en; 2023 [accessed 17 March 2026]."},{"key":"10.1016\/j.diabres.2026.113520_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105808","article-title":"The role of 5\u03b1-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies","volume":"207","author":"Nikolaou","year":"2021","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.diabres.2026.113520_b0205","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.juro.2007.11.033","article-title":"The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer","volume":"179","author":"Tindall","year":"2008","journal-title":"J Urol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:26:03Z","timestamp":1793121963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0168822726004407"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113520","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of incident diabetes after initiation of 5\u03b1-reductase inhibitor plus \u03b1-blocker combination therapy: A nationwide cohort study with age-specific analyses","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113520"}}